Loading...
Få 200 $ for at oprette en Interactive Brokers-konto med vores link: Opret IBKR-konto. Læs vores analyse af Interactive Brokers
- Ticker
- BAVA.CO
- Price
- 193.75
- Stock movement down
- -0.20 (-0.10%)
- Company name
- Bavarian Nordic
- Exchange
- (CO ,
- Currency
- DKK )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 15.39B
- Ent værdi
- 15.30B
- Pris/omsætning
- 2.24
- Pris/bog
- 1.17
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- 6.30
- Fremtidig P/E
- 20.14
- PEG
- -
- EPS-vekst
- -
- 1 års afkast (CAGR)
- 12.94%
- 3 års afkast (CAGR)
- -4.27%
- 5 års afkast (CAGR)
- -4.98%
- 10 års afkast (CAGR)
- 0.81%
Senest opdateret: 2026-02-26
UDBYTTE
BAVA.CO betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | 6.30 |
| Pris til OCF | 4.91 |
| Pris til FCF | 11.99 |
| Pris til EBITDA | 8.39 |
| EV i forhold til EBITDA | 8.34 |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 2.24 |
| Pris til egenkapital | 1.17 |
| EV i forhold til salg | 2.22 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 78.24M |
| EPS (TTM) | 31.24 |
| FCF pr. aktie (TTM) | 16.40 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 6.89B |
| Bruttofortjeneste (TTM) | 3.74B |
| Driftsindkomst (TTM) | 2.49B |
| Nettoindkomst (TTM) | 2.44B |
| EPS (TTM) | 31.24 |
| EPS (1 år frem) | 9.77 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 54.33% |
| Driftsmargin (TTM) | 36.21% |
| Fortjenstmargin (TTM) | 35.50% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 2.09B |
| Nettotilgodehavender | 1.23B |
| Omsætningsaktiver i alt | 6.89B |
| Goodwill | 0.00 |
| Immaterielle aktiver | 6.02B |
| Ejendomme, anlæg og udstyr | 2.19B |
| Sum aktiver | 15.16B |
| Kreditor | 1.10B |
| Kortfristet/nuværende langsigtet gæld | 134.04M |
| Summen af kortfristede forpligtelser | 1.80B |
| Sum gæld | 2.00B |
| Aktionærernes egenkapital | 13.16B |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | 3.13B |
| Investeringsudgifter (TTM) | 1.85B |
| Fri pengestrøm (TTM) | 1.28B |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | 18.58% |
| Afkast af aktiver | 16.13% |
| Afkast af investeret kapital | 18.56% |
| Kontant afkast af investeret kapital | 9.75% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 196.80 |
| Daglig høj | 197.60 |
| Daglig lav | 194.25 |
| Daglig volumen | 169K |
| Højeste gennem alle tider | 401.70 |
| 1 års analytiker estimat | - |
| Beta | 1.10 |
| EPS (TTM) | 31.24 |
| Udbytte pr. aktie | 0.00 |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 12 Mar 2026 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| BAVA.CO | S&P500 | |
| Nuværende prisfald fra top notering | -51.77% | -1.82% |
| Højeste prisfald | -91.83% | -56.47% |
| Højeste efterår dato | 30 Sep 2002 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -48.18% | -10.84% |
| Gennemsnitlig tid til nyt højdepunkt | 98 days | 12 days |
| Maks. tid til nyt højdepunkt | 1935 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
15.39B
Markedsværdi kategori
Large-cap
Beskrivelse
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Personale
1738
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Denmark
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Monkeypox Market Competitive Landscape 2026: Comprehensive Insights About 8+ Companies and 10+ Drugs
Emerging opportunities in the monkeypox treatment and prevention market include innovative vaccine developments by companies such as Bavarian Nordic, BioNTech, and Moderna. The focus is on mRNA-based ...
18. februar 2026
COPENHAGEN, Denmark, February 18, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced a new order valued at USD 22.5 million from the Public Health Agency of Canada (PHAC) for the Company’s mpox an...
18. februar 2026
Bavarian Nordic (CPSE:BAVA) has drawn investor attention after recent share price moves, with a 0.6% decline on the day and mixed returns across the past week, month, and past 3 months. See our latest...
16. februar 2026
Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public Preparedness.2026 guidance reflects continued growth in Travel Healt...
12. februar 2026
COPENHAGEN, Denmark, February 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 7, 2026, has now been completed, reachin...
9. februar 2026
COPENHAGEN, Denmark, February 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase sha...
2. februar 2026
Agreement to enable the first entry in Latin America for Bavarian Nordic’s chikungunya vaccinePotential to expand agreement to cover rest of Latin America COPENHAGEN, Denmark, January 23, 2026 – Bavar...
23. januar 2026
Bavarian Nordic (CPSE:BAVA) has been drawing attention after recent share moves, with the stock showing mixed returns over the past year that contrast with modest annual revenue and net income changes...
10. januar 2026
If you are wondering whether Bavarian Nordic is attractively priced right now, you are not alone. The stock has drawn attention from investors trying to work out if the current level reflects its fund...
10. januar 2026
COPENHAGEN, Denmark, January 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the share buy-back program announced on December 2, 2025, under which the Company intends to ...
7. januar 2026
Næste side